SIRT1 profile update in high-risk pregnancies and preeclampsia: A novel comprehensive cohort study

Abstract

Abstract The preeclampsia etiology is unclearly understood, becoming considerable concern as an aging-related disease. Accelerated prematurity of cell death associated with decreased Sirtuin (SIRT)1 activity. This study was designed to estimate the SIRT1 serum profile in high-risk pregnancies to preeclampsia development probability. This study was conducted from January to October 2020, 305 screened pregnant women with a gestational age of 4 weeks up to < 20 weeks were enrolled in a prospective cohort study up to sixth weeks postpartum. Women with existing complications during follow-up such as antenatal bleeding, placental abruption, hepatitis, abortion, death, and rejection under follow-up were excluded. Serum SIRT1 variance that was measured by ELISA at the baseline and endline of the study were investigated with the preeclampsia progression. Our results demonstrate, that constan serum SIRT1 concentration until third trimester of pregnancy tend to increased development of preeclampsia. In contrast, SIRT1 concentrations at normal pregnancy outcomes appear to be higher in late pregnancy (gestational age > 37 weeks). Importantly, we found that serum SIRT1 concentration was significantly reduced in pregnancy-developed preeclampsia than in normal pregnancy (p < 0.001). We concluded that the lack of elevating serum SIRT1 concentrations until > 20 weeks of gestation increases the likelihood of developing preeclampsia. Ultimately, we provide a translational perspective to driving accelerating SIRT1 serum concentrations in women with at-risk pregnancies from early pregnancy towards > 20 weeks gestation, becoming a further study that promises effort to prevent preeclampsia and improve women's quality of life.